Search Results

Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com.

Compugen Ltd. today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.

Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i ® , Scientist.com’s Supplier Pre-assessment Program.

Halberd Corporation (OTC PINK:HALB) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd’s patented low dose naltrexone combo product(s) worldwide.

OrganaBio products and services can now be accessed via the Science Exchange and Scientist.com platforms.

Discover how MedicalLicensing.com has revolutionized the medical licensing process for top healthcare professionals and businesses.

Compugen Ltd. announced the simultaneous online publication of a peer reviewed paper titled ‘Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects’ link, in Cancer Immunology Research, a journal of the American Association for Cancer Research with a presentation at the American Association for Cancer Research annual meeting on April 5-11, 2024, in San Diego, California.

Compugen Ltd. today announced that the first patient has been dosed in the triple immunotherapy combination proof-of-concept study evaluating COM701, Compugen’s potential first-in-class anti-PVRIG antibody, with COM902, Compugen’s potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer.

InnerScope Hearing Technologies Inc. announced has retained SmallCapVoice.com, a seasoned, yet dynamic firm with a focus on compliant investor relations, digital marketing, and community management services tailored for publicly traded companies.

Compugen Ltd. today announced that it will host a conference call at 8:30 AM ET today, to discuss the exclusive license agreement with Gilead announced today, for the development and commercialization of its anti-IL-18 binding protein program including COM503, a pre-clinical potential first-in-class high affinity antibody targeting IL-18 binding protein with potential to treat multiple tumor types.